Definitive Healthcare (NASDAQ:DH) has been evaluated by 4 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target has been adjusted to $9.88, down from $10.38, reflecting a 4.82% decline. Analysts from firms like Stifel, Morgan Stanley, Barclays, and Canaccord Genuity have updated their ratings and price targets, indicating a nuanced view of the company's prospects. Definitive Healthcare, a provider of healthcare commercial intelligence, has shown a revenue growth of 8.8% but lags behind industry peers, with a notable net margin of -15.52% and a debt-to-equity ratio of 0.31.